Factors | n = 359 |
---|---|
Sex (Male/Female) | 238/121 |
Age (years) | 71 (64, 79)d |
Height (m) | 1.64 (1.55, 1.71)d |
Body weight (kg) | 62.55 (54.68, 72.40)d |
Body mass index (kg/m2) | 23.41 (21.15, 25.65)d |
Serum creatinine (mg/dL) | 0.88 (0.74, 1.03)d |
Ccr (mL/min) | 64.63 (47.56, 86.03)d |
Daily dose of bepridil (mg/kg body weight) | 1.58 (1.24, 2.02)d |
Period of bepridil treatment (day) | 356 (124, 1404)d |
Plasma bepridil concentration (ng/mL) | 300 (157, 491)d |
C/D ratio of bepridil (ng/mL) / (mg/day/kg) | 186 (108, 278) |
LVEF (%) | 65.1 (59.1, 69.9)d |
 HFrEFa, n (%) | 14 (3.9) |
 HFmrEFb, n (%) | 28 (7.8) |
 HFpEFc, n (%) | 317 (88.3) |
Patient’s medical history, n (%) | |
 Coronary artery bypass graft | 3 (0.8) |
 Graft replacement | 1 (0.3) |
 Atrial fibrillation | 346 (94.3) |
 Heart valve replacement or formation | 8 (2.2) |
Concomitant drugs for HF and comorbidities, n (%) | |
 ACE inhibitor/ARB | 116 (32.3) |
 β-blocker | 218 (60.7) |
 Calcium-channel blocker | 98 (27.3) |
 Statins | 111 (30.9) |
 Diuretics | 89 (24.8) |
 Antidiabetic drugs | 40 (11.1) |
 Anticoagulant drugs | 286 (79.7) |